Organigram Global (OGI) Competitors $1.76 -0.06 (-3.04%) As of 12:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OGI vs. ACB, CGC, CRON, SNDL, TLRY, VFF, URGN, RAPP, ABUS, and PHATShould you be buying Organigram Global stock or one of its competitors? The main competitors of Organigram Global include Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON), SNDL (SNDL), Tilray Brands (TLRY), Village Farms International (VFF), Urogen Pharma (URGN), Rapport Therapeutics (RAPP), Arbutus Biopharma (ABUS), and Phathom Pharmaceuticals (PHAT). Organigram Global vs. Its Competitors Aurora Cannabis Canopy Growth Cronos Group SNDL Tilray Brands Village Farms International Urogen Pharma Rapport Therapeutics Arbutus Biopharma Phathom Pharmaceuticals Aurora Cannabis (NASDAQ:ACB) and Organigram Global (NASDAQ:OGI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends. Is ACB or OGI more profitable? Organigram Global has a net margin of 2.86% compared to Aurora Cannabis' net margin of -5.66%. Aurora Cannabis' return on equity of -1.49% beat Organigram Global's return on equity.Company Net Margins Return on Equity Return on Assets Aurora Cannabis-5.66% -1.49% -1.06% Organigram Global 2.86%-8.19%-5.79% Do insiders and institutionals believe in ACB or OGI? 47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 34.6% of Organigram Global shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by company insiders. Comparatively, 0.1% of Organigram Global shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts prefer ACB or OGI? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.00Organigram Global 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer ACB or OGI? In the previous week, Aurora Cannabis and Aurora Cannabis both had 2 articles in the media. Organigram Global's average media sentiment score of 1.78 beat Aurora Cannabis' score of 0.93 indicating that Organigram Global is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organigram Global 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk & volatility, ACB or OGI? Aurora Cannabis has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500. Comparatively, Organigram Global has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Which has preferable valuation & earnings, ACB or OGI? Aurora Cannabis has higher revenue and earnings than Organigram Global. Aurora Cannabis is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurora Cannabis$357.88M0.80$1.63M-$0.19-26.55Organigram Global$223.82M1.05-$33.39M$0.0535.10 SummaryAurora Cannabis beats Organigram Global on 9 of the 15 factors compared between the two stocks. Get Organigram Global News Delivered to You Automatically Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGI vs. The Competition Export to ExcelMetricOrganigram GlobalMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$237.11M$10.31B$5.65B$10.32BDividend YieldN/A1.90%5.68%4.61%P/E Ratio35.3120.0775.6626.31Price / Sales1.0529.49521.00169.30Price / CashN/A24.3737.5661.52Price / Book0.853.3412.996.34Net Income-$33.39M$212.47M$3.29B$270.94M7 Day Performance-6.65%-2.88%-0.03%0.29%1 Month Performance7.67%-4.25%4.13%6.89%1 Year Performance0.86%-10.83%69.08%29.31% Organigram Global Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGIOrganigram Global1.3773 of 5 stars$1.76-3.0%N/A+0.6%$237.11M$223.82M35.31860Positive NewsACBAurora Cannabis0.4117 of 5 stars$4.97+2.1%N/A-9.8%$274.93M$357.88M-26.161,130CGCCanopy Growth1.1434 of 5 stars$1.39+1.5%N/A-69.1%$328.59M$225.65M-0.463,150Positive NewsCRONCronos Group2.5495 of 5 stars$2.55+0.8%N/A+26.0%$968.72M$130.28M51.00450SNDLSNDL3.8529 of 5 stars$2.50+3.7%$4.50+80.0%+26.0%$633.29M$671.81M-9.262,516Positive NewsGap DownTLRYTilray Brands2.8545 of 5 stars$1.18+5.4%$1.94+64.2%-26.7%$1.23B$210.48M-0.512,842Gap DownVFFVillage Farms International1.8648 of 5 stars$2.64flatN/A+210.2%$297.38M$340.18M29.341,400News CoverageGap DownURGNUrogen Pharma4.2172 of 5 stars$18.06-3.9%$32.00+77.2%+37.7%$869.30M$90.40M-5.44200Positive NewsRAPPRapport Therapeutics3.0722 of 5 stars$24.73+4.1%$31.00+25.4%+26.0%$867.19MN/A-9.89N/AABUSArbutus Biopharma2.1777 of 5 stars$4.53+1.6%$5.00+10.4%+11.7%$854.98M$15.42M-15.6290Positive NewsPHATPhathom Pharmaceuticals2.7538 of 5 stars$11.48-3.0%$17.50+52.4%-32.0%$839.98M$114.04M-2.43110 Related Companies and Tools Related Companies ACB Competitors CGC Competitors CRON Competitors SNDL Competitors TLRY Competitors VFF Competitors URGN Competitors RAPP Competitors ABUS Competitors PHAT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OGI) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organigram Global Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organigram Global With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
